ADCT ADC Therapeutics S.A.
Healthcare$3.51+3.54%ClosedMarket Cap: $446.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.42
P/S
5.45
EV/EBITDA
-7.08
DCF Value
$-10.63
FCF Yield
-26.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.7%
Operating Margin
-149.6%
Net Margin
-173.0%
ROE
65.3%
ROA
-47.0%
ROIC
-51.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $20.9M | 82.7% | $-25.2M | $-33.0M | $— | — |
| Q4 null | $23.1M | 92.6% | $-18.1M | $-6.4M | $— | — |
| FY null | $81.4M | 90.6% | $-108.4M | $-142.6M | $— | — |
| Q3 null | $16.4M | 92.7% | $-31.0M | $-41.0M | $— | — |
| Q2 null | $18.8M | 95.6% | $-44.1M | $-56.6M | $— | — |
| Q1 null | $23.0M | 91.1% | $-28.5M | $-38.6M | $— | — |
| Q4 null | $16.9M | 91.9% | $-32.4M | $-30.7M | $— | — |
| FY null | $70.8M | 91.6% | $-130.7M | $-157.8M | $— | — |
| Q3 null | $18.5M | 95.4% | $-35.6M | $-44.0M | $— | — |
| Q2 null | $17.4M | 93.0% | $-29.0M | $-36.5M | $— | — |
| Q1 null | $18.1M | 86.1% | $-33.6M | $-46.6M | $— | — |
| Q4 2023 | $16.8M | -645.4% | $-40.0M | $-85.0M | $-1.03 | — |